“I sit up for sharing how AllerGenis is shaping the way forward for meals allergy diagnostics and the a number of developments we’re working laborious to deliver to sufferers and caregivers throughout the nation,” mentioned Dr. Kearney. “This consists of our latest innovation – a peanut sensitivity assay – that may decide the quantity of peanut protein more likely to trigger an allergic response when ingested which can even be used when assessing the development of peanut allergy desensitization. This development can positively affect the lives of tens of millions of sufferers and caregivers who’re navigating the complexities of life with a meals allergy whereas additionally offering a neater option to safely navigate meals labeling.”
The AllerGenis’ proprietary epitope mapping expertise permits exact monitoring of the immune system’s response to the surroundings together with meals and viruses, utilizing solely a small quantity of blood from a affected person. The course of makes use of progressive expertise and machine studying to create a real breakthrough in meals allergy diagnositcs that determines correlating scientific outcomes with excessive precision.
To register for the IAFNS Annual assembly, and to realize entry to this session and extra, please go to the group’s registration web page here.
About AllerGenis
Established in 2017 and positioned in Hatfield, PA, AllerGenis makes use of predictive knowledge analytics for the detection and administration of life-threatening immune response issues. Amassing the world’s largest database of phenotypic affected person knowledge derived from epitope mapping, scientific historical past and patient-reported outcomes to realize scientific insights, AllerGenis is main the sector in creating precision, data-driven diagnostics to assist healthcare suppliers extra precisely and safely diagnose, assess and monitor sufferers with meals allergy symptoms. The firm was based by way of a collaboration with Hugh Sampson MD, of the Icahn School of Medicine at Mount Sinai. Mount Sinai Health System has licensed its proprietary epitope mapping platform to AllerGenis. For extra details about AllerGenis, go to www.allergenis.com and comply with the corporate on LinkedIn, Twitter and Facebook.
SOURCE AllerGenis
